- Home
- EVMN vs SIGA Comparison
EVMN vs SIGA Comparison
Compare EVMN & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EVMN | SIGA |
|---|---|---|
| Founded | 2020 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.6M | 487.7M |
| IPO Year | 2025 | 1997 |
Fundamental Metrics
Financial Performance| Metric | EVMN | SIGA |
|---|---|---|
| Price | $28.46 | $6.64 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $44.17 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 318.0K |
| Earning Date | 06-10-2026 | 03-10-2026 |
| Dividend Yield | N/A | ★ 8.98% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.03 |
| Revenue | $13,000,000.00 | ★ $172,249,641.00 |
| Revenue This Year | $89.43 | N/A |
| Revenue Next Year | N/A | $132.36 |
| P/E Ratio | ★ N/A | $6.48 |
| Revenue Growth | ★ 160.00 | N/A |
| 52 Week Low | $13.89 | $4.95 |
| 52 Week High | $33.20 | $9.62 |
Technical Indicators
Market Signals| Indicator | EVMN | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 69.55 | 49.34 |
| Support Level | $15.97 | $6.47 |
| Resistance Level | $33.20 | $6.84 |
| Average True Range (ATR) | 3.05 | 0.24 |
| MACD | 0.89 | -0.03 |
| Stochastic Oscillator | 74.38 | 24.41 |
Price Performance
Historical ComparisonAbout EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.